These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 19561231)

  • 21. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma.
    Sutton LM; Han JS; Molberg KH; Sarode VR; Cao D; Rakheja D; Sailors J; Peng Y
    Am J Clin Pathol; 2010 Nov; 134(5):782-7. PubMed ID: 20959661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.
    Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu S
    Ann Clin Lab Sci; 2006; 36(2):137-43. PubMed ID: 16682508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
    Yu KD; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
    [No Abstract]   [Full Text] [Related]  

  • 27. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ; Cui X; Hilsenbeck SG; Lee AV
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.
    Diallo R; Ting E; Gluz O; Herr A; Schütt G; Geddert H; Mohrmann S; Gabbert HE; Nitz U; Poremba C
    Verh Dtsch Ges Pathol; 2006; 90():177-85. PubMed ID: 17867595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR expression and gene copy number in triple-negative breast carcinoma.
    Gumuskaya B; Alper M; Hucumenoglu S; Altundag K; Uner A; Guler G
    Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications.
    Badve S; Nakshatri H
    J Clin Pathol; 2009 Jan; 62(1):6-12. PubMed ID: 18794199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers.
    Kim NH; Lim HY; Im KS; Kim JH; Sur JH
    J Comp Pathol; 2013 May; 148(4):298-306. PubMed ID: 23079102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
    Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
    Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.
    Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S
    Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?
    Bird PA; Hill AG; Houssami N
    Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.